Advertisement ProBioGen and Boehringer forge strategic alliance - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

ProBioGen and Boehringer forge strategic alliance

Biotechnology firm ProBioGen has signed a strategic production agreement with Boehringer Ingelheim.

Under the agreement, ProBioGen will integrate some of Boehringer’s technologies to accommodate a seamless process and technology transfer from pilot and medium-scale to commercial-scale production capacities.

ProBioGen’s clients will thereby gain access to Boehringer’s manufacturing technology platform and large-scale commercial production. In addition, Boehringer’s clients and partners will benefit from ProBioGen’s expertise in process development and manufacturing.

Michael Schlenk, CEO of ProBioGen, said: “ProBioGen’s strategic production alliance with Boehringer Ingelheim is an important milestone in our commercial strategy. For one, our clients will gain access to one of the leading commercial-scale production platforms, but we will also be able to expand our client base and have started to build additional production capabilities to meet increased client demand.”